# Efficacy of Sertraline Combined With Intestinal Microecological Therapy in Adolescents With Moderate Depression and Suicidal Ideation and Its Effects on Serum Inflammatory Factors

**Authors:** Lei Zhang, Dongrong Zhao, Jiayu Huang, Sha Liu, Naihong Xu

PMC · DOI: 10.62641/aep.v54i1.2127 · Actas Españolas de Psiquiatría · 2026-02-15

## TL;DR

Combining sertraline with a probiotic improved depression and reduced inflammation in adolescents with moderate depression and suicidal thoughts.

## Contribution

Demonstrates that combining sertraline with a probiotic enhances antidepressant efficacy via anti-inflammatory effects in adolescents.

## Key findings

- Combination therapy reduced severe depression and anxiety more effectively than monotherapy.
- Serum inflammatory markers like IL-6, IL-1β, TNF-α, and CRP were significantly lower in the combination group.
- IL-6 and CRP showed strong positive correlations with depression scores.

## Abstract

Adolescents with moderate depression and suicidal ideation constitute a high-risk psychiatric population. Major depressive disorder with suicidal ideation in this age group is a disabling psychiatric disorder. Current selective serotonin reuptake inhibitor treatments are limited by their low efficacy rates (approximately 50%–60%) and delayed onset of action. Informed by the gut–brain axis theory, this study aimed to evaluate the synergistic efficacy and anti-inflammatory mechanisms of sertraline combined with a Bacillus subtilis probiotic preparation in this high-risk population.

This retrospective cohort study included 160 adolescents meeting International Classification of Diseases 10th Revision diagnostic criteria were identified and categorised into either monotherapy (sertraline) or combination therapy (sertraline + probiotics) groups. Over a 12-week treatment period, clinical symptoms were assessed using the Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale and Beck Scale for Suicide Ideation-Chinese Version, and serum inflammatory factors, namely, interleukin-6 (IL-6), interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α) and C-reactive protein (CRP) and peripheral blood inflammatory ratios, namely, platelet-to-lymphocyte, neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios, were measured.

The proportion of patients with severe depression was significantly reduced in the combination group (1.25% vs. 7.5%, p = 0.004), and anxiety symptoms showed significant improvement (severe anxiety proportion: 1.25% vs. 11.25%, p = 0.008). Biomarker analysis revealed significantly reduced levels of IL-6 (p = 0.007), IL-1β (p = 0.002), TNF-α (p = 0.005) and CRP (p = 0.001) in the combination group, and IL-6 and CRP showed strong positive correlations with depression scores (r = 0.35–0.39).

This study confirms that modulating the intestinal smicroecology can enhance antidepressant efficacy by reducing neuroinflammation.

## Linked entities

- **Chemicals:** sertraline (PubChem CID 68617)
- **Diseases:** depression (MONDO:0002050), major depressive disorder (MONDO:0002009)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}
- **Diseases:** MDD (MESH:D003865), Anxiety Symptoms (MESH:D001008), Suicidal Ideation (MESH:D001072), insomnia (MESH:D007319), psychiatric (MESH:D001523), dysbiosis (MESH:D064806), Anxiety (MESH:D001007), neuroinflammation (MESH:D000090862), Inflammatory (MESH:D007249), cognitive  dysfunction (MESH:D003072), Depression (MESH:D003866), gastrointestinal discomfort (MESH:D005767), dizziness (MESH:D004244), symptoms (MESH:D012816)
- **Chemicals:** kynurenine (MESH:D007737), cortisol (MESH:D006854), tryptophan (MESH:D014364), serotonin (MESH:D012701), LPS (MESH:D008070), Sertraline (MESH:D020280), -aminobutyric acid (MESH:D000613)
- **Species:** Lactobacillus (genus) [taxon 1578], Bacillus subtilis (species) [taxon 1423], Homo sapiens (human, species) [taxon 9606], Bifidobacterium (genus) [taxon 1678]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946716/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946716/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946716/full.md

---
Source: https://tomesphere.com/paper/PMC12946716